Gain of function of mutant p53 by coaggregation with multiple tumor suppressors

被引:432
作者
Xu, Jie [1 ]
Reumers, Joke [1 ]
Couceiro, Jose R. [1 ]
De Smet, Frederik [1 ]
Gallardo, Rodrigo [1 ]
Rudyak, Stanislav [1 ]
Cornelis, Ann [2 ]
Rozenski, Jef [3 ]
Zwolinska, Aleksandra [4 ]
Marine, Jean-Christophe [4 ]
Lambrechts, Diether [5 ]
Suh, Young-Ah [6 ]
Rousseau, Frederic [1 ]
Schymkowitz, Joost [1 ]
机构
[1] Vrije Univ Brussel, Flanders Inst Biotechnol, SWITCH Lab, Brussels, Belgium
[2] Reg Ziekenhuis Heilig Hart, Dept Pathol, Tienen, Belgium
[3] Katholieke Univ Leuven, Rega Inst Med Res, Med Chem Lab, B-3000 Louvain, Belgium
[4] Katholieke Univ Leuven, Flanders Inst Biotechnol, Dept Mol & Dev Genet, Lab Mol Canc Biol, Louvain, Belgium
[5] Katholieke Univ Leuven, Flanders Inst Biotechnol, Vesalius Res Ctr, Louvain, Belgium
[6] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA
基金
中国国家自然科学基金;
关键词
DNA-BINDING; WILD-TYPE; PROGNOSTIC-SIGNIFICANCE; ACTIVATING MUTATIONS; PROTEIN AGGREGATION; LI-FRAUMENI; CANCER; P73; P63; TRANSFORMATION;
D O I
10.1038/nchembio.546
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Many p53 missense mutations possess dominant-negative activity and oncogenic gain of function. We report that for structurally destabilized p53 mutants, these effects result from mutant-induced coaggregation of wild-type p53 and its paralogs p63 and p73, thereby also inducing a heat-shock response. Aggregation of mutant p53 resulted from self-assembly of a conserved aggregation-nucleating sequence within the hydrophobic core of the DNA-binding domain, which becomes exposed after mutation. Suppressing the aggregation propensity of this sequence by mutagenesis abrogated gain of function and restored activity of wild-type p53 and its paralogs. In the p53 germline mutation database, tumors carrying aggregation-prone p53 mutations have a significantly lower frequency of wild-type allele loss as compared to tumors harboring nonaggregating mutations, suggesting a difference in clonal selection of aggregating mutants. Overall, our study reveals a novel disease mechanism for mutant p53 gain of function and suggests that, at least in some respects, cancer could be considered an aggregation-associated disease.
引用
收藏
页码:285 / 295
页数:11
相关论文
共 48 条
[1]   Protein aggregation diseases: pathogenicity and therapeutic perspectives [J].
Aguzzi, Adriano ;
O'Connor, Tracy .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) :237-248
[2]   Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains [J].
Ang, Hwee Ching ;
Joerger, Andreas C. ;
Mayer, Sebastian ;
Fersht, Alan R. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (31) :21934-21941
[3]   Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73 [J].
Bensaad, K ;
Le Bras, M ;
Unsal, K ;
Strano, S ;
Blandino, G ;
Tominaga, O ;
Rouillard, D ;
Soussi, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (12) :10546-10555
[4]   Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors [J].
Boominathan, Lakshmanane .
MOLECULAR CANCER, 2007, 6
[5]   When mutants gain new powers: news from the mutant p53 field [J].
Brosh, Ran ;
Rotter, Varda .
NATURE REVIEWS CANCER, 2009, 9 (10) :701-713
[6]   Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy [J].
Bullock, AN ;
Henckel, J ;
Fersht, AR .
ONCOGENE, 2000, 19 (10) :1245-1256
[7]   Rescuing the function of mutant p53 [J].
Bullock, AN ;
Fersht, A .
NATURE REVIEWS CANCER, 2001, 1 (01) :68-76
[8]   Thermodynamic stability of wild-type and mutant p53 core domain [J].
Bullock, AN ;
Henckel, J ;
DeDecker, BS ;
Johnson, CM ;
Nikolova, PV ;
Proctor, MR ;
Lane, DP ;
Fersht, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14338-14342
[9]   p53 family members in myogenic differentiation and rhabdomyosarcoma development [J].
Cam, Hakan ;
Griesmann, Heidi ;
Beitzinger, Michaela ;
Hofmann, Lars ;
Beinoraviciute-Kellner, Rasa ;
Sauer, Markus ;
Huettinger-Kirchhof, Nicole ;
Oswald, Claudia ;
Friedl, Peter ;
Gattenloehner, Stefan ;
Burek, Christof ;
Rosenwald, Andreas ;
Stiewe, Thorsten .
CANCER CELL, 2006, 10 (04) :281-293
[10]   How many mutant p53 molecules are needed to inactivate a tetramer? [J].
Chan, WM ;
Siu, WY ;
Lau, A ;
Poon, RYC .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (08) :3536-3551